- Conditions
- Stargardt's Disease
- Interventions
- Long term follow up in all patients who received SAR422459 in previous study TDU13583
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2033
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dominantly Inherited Stargardt's Disease (STGD3)
- Interventions
- Over the counter DHA/EPA dietary supplementation
- Dietary Supplement
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 105 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- MA09-hRPE
- Biological
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania
- Conditions
- Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
- Interventions
- Not listed
- Lead sponsor
- Splice Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 14
- States / cities
- San Diego, California • Aurora, Colorado • Gainesville, Florida + 10 more
- Conditions
- Stargardt's Disease
- Interventions
- SAR422459
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 4
- States / cities
- Miami, Florida • Iowa City, Iowa • Portland, Oregon + 1 more
- Conditions
- Retinal Degeneration, Retinitis Pigmentosa, Stargardt's Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 5 Years to 100 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration
- Interventions
- Docosahexaenoic Acid (DHA) Dietary Supplement
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- MA09-hRPE
- Biological
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania
- Conditions
- Retinal Diseases, Stargardt's Disease, Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- Retina Institute of Hawaii
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 4
- States / cities
- Hilo, Hawaii • Honolulu, Hawaii • Kahului, Hawaii + 1 more
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- avacincaptad pegol, Sham
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more